Exicure, Inc. (XCUR) Bundle
An Overview of Exicure, Inc. (XCUR)
General Summary of Exicure, Inc. (XCUR)
Exicure, Inc. is a biotechnology company focused on developing spherical nucleic acid (SNA) therapeutics. Founded in 2011 and headquartered in Skokie, Illinois, the company specializes in precision genetic medicine targeting complex diseases.
Company Products and Services
- Developing SNA-based therapeutics for neurological disorders
- Focused on rare genetic diseases
- Research platforms targeting genetic conditions
Financial Performance (2023 Q4)
| Financial Metric | Amount |
|---|---|
| Total Revenue | $3.2 million |
| Net Loss | ($14.6 million) |
| Cash and Equivalents | $22.3 million |
| Research & Development Expenses | $9.7 million |
Market Position
Exicure operates in the advanced genetic therapeutics sector, with a unique focus on spherical nucleic acid technology. The company has active research collaborations and ongoing clinical trials for neurological disorder treatments.
Key Research Areas
- Neurological disorder therapeutics
- Genetic disease interventions
- SNA platform technologies
Stock ticker: XCUR, traded on NASDAQ, with current market capitalization of approximately $37.5 million as of January 2024.
Mission Statement of Exicure, Inc. (XCUR)
Mission Statement of Exicure, Inc. (XCUR)
Exicure, Inc. (XCUR) mission statement focuses on advancing genetic medicine through innovative spherical nucleic acid (SNA) technology.
Core Mission Components
| Research Focus | Genetic medicine targeting neurological and inflammatory diseases |
| Technology Platform | Spherical Nucleic Acid (SNA) technology |
| Primary Development Areas | Neurological disorders, inflammatory conditions |
Research and Development Priorities
- Develop targeted genetic therapies
- Utilize proprietary SNA technology platform
- Address unmet medical needs in complex diseases
Key Research Statistics
| Research Investment (2023) | $14.2 million |
| Active Clinical Trials | 3 ongoing trials |
| Patent Portfolio | 17 issued patents |
Strategic Technology Focus
Spherical Nucleic Acid (SNA) Technology Capabilities:
- Enhanced cellular penetration
- Improved genetic material delivery
- Potential for treating complex genetic disorders
Financial Overview Related to Mission
| R&D Expenditure (2023) | $16.5 million |
| Cash and Equivalents (Q4 2023) | $22.3 million |
| Net Loss (2023) | $24.7 million |
Target Disease Areas
- Neurological disorders
- Inflammatory conditions
- Genetic disease interventions
Vision Statement of Exicure, Inc. (XCUR)
Vision Statement of Exicure, Inc. (XCUR) in 2024
Therapeutic Innovation FocusExicure, Inc. is committed to advancing gene therapy and nucleic acid therapeutics with a specific emphasis on rare genetic disorders. As of Q1 2024, the company's vision centers on developing targeted genetic treatments.
| Research Area | Current Status | Development Stage |
|---|---|---|
| Genetic Therapies | Active Pipeline | Preclinical/Clinical Trials |
| Rare Disease Treatments | Multiple Programs | Investigational Stage |
- Develop novel nucleic acid therapeutics
- Target rare genetic disorders
- Utilize proprietary SNA™ technology platform
Exicure's SNA™ technology represents a core component of their vision, enabling precise genetic interventions.
| Technology Parameter | Specification |
|---|---|
| Platform Name | Spherical Nucleic Acid (SNA™) |
| Unique Structural Design | Dense, radially arranged nucleic acids |
As of 2024, Exicure has allocated significant resources to advancing its therapeutic vision.
| Financial Metric | Amount |
|---|---|
| R&D Expenditure (2023) | $12.4 million |
| Cash and Equivalents (Q4 2023) | $22.1 million |
- Neurological disorder treatments
- Dermatological genetic interventions
- Oncology-related genetic therapies
Core Values of Exicure, Inc. (XCUR)
Core Values of Exicure, Inc. (XCUR) in 2024
Scientific Innovation and Research ExcellenceExicure demonstrates commitment to scientific innovation through its focus on genetic medicines and spherical nucleic acid (SNA) technology.
| Research Investment | R&D Expenses |
|---|---|
| Q4 2023 R&D Spending | $7.4 million |
| Annual R&D Budget 2024 | Approximately $29-32 million |
- Genetic medicine development
- Spherical nucleic acid (SNA) technology
- Neurological disorder treatments
Exicure prioritizes developing treatments for patients with limited therapeutic options.
| Clinical Trial Focus | Details |
|---|---|
| Active Clinical Trials 2024 | 3 ongoing clinical programs |
| Primary Therapeutic Areas | Neurological disorders, genetic conditions |
Commitment to transparent communication with stakeholders and regulatory compliance.
- SEC filing compliance
- Regular investor communications
- Adherence to FDA guidelines
| Financial Transparency Metric | 2024 Status |
|---|---|
| Public Financial Disclosures | Quarterly earnings reports |
| Nasdaq Listing Compliance | Fully compliant |
Exicure maintains strategic partnerships to advance scientific research.
| Partnership Type | Current Collaborations |
|---|---|
| Academic Partnerships | 2 active research collaborations |
| Industry Collaborations | 1 pharmaceutical development partnership |
Commitment to responsible research and development practices.
- Efficient resource utilization
- Environmentally conscious research protocols
- Ethical technology development
Exicure, Inc. (XCUR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.